BTK/PI3K/BRD4 triple-inhibitors present a potential solution to the toxicity that often plagues combination therapeutic strategies that are necessary to overcome CLL progression and drug resistance. This evidence concerns the gene BRD4 and B-cell chronic lymphocytic leukemia.